Journal
JOURNAL OF NUTRITION
Volume 144, Issue 1, Pages 49-54Publisher
AMER SOC NUTRITION-ASN
DOI: 10.3945/jn.113.182725
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [810722881]
- Chongqing Science and Technology Commission [CSTC, 2011AB5040]
- Danone Nutrition Dietary Nutrition Research Center
- Mission Fund [DIC2013-08]
Ask authors/readers for more resources
Daidzein (one of the major isoflavones) can be metabolized to equol in certain individuals. The effects of isoflavones alone and equol status on lipid profiles are still controversial. To evaluate the 6-mo effects of daidzein on cardiovascular risk factors in hypercholesterolemic individuals and the interactions of these effects with equol status and estrogen receptor (ESR) genotypes, we conducted a randomized, double-blind, placebo-controlled trial consisting of 210 hypercholesterolemic adults (40-65 y old). The participants were randomly assigned (177 completed) to consume placebo, 40 mg daidzein (DAI40), or 80 mg daidzein (DAI80) daily for 6 mo. Daidzein decreased serum triglycerides (TGs) by 0.15 +/- 0.62 mmol/L (mean +/- SD) and 0.24 +/- 0.61 mmol/L and decreased serum uric acid by 23 +/- 47 mu mol/L and 29 +/- 44 mu mol/L in the DAI40 and DAI80 groups, respectively. These reductions in the DAI40 and DAI80 groups were greater than those in the placebo group (P<0.05). Other blood lipids, glucose, insulin, or glycated hemoglobin did not significantly change after daidzein treatment. No dose-dependent effects of daidzein were found. The reduction of TGs was influenced by the ESR genotype, with a greater effect observed in participants with the GA genotype compared with those with the GG genotype of ESR-beta Rsal. These effects were not influenced by equol status. Six-month supplementation of daidzein significantly decreased TGs and uric acid. ESR-beta Rsal genotype, not equol status, influenced daidzein's effects-on TGs. Daidzein consumption may be effective to improve cardiovascular risk factors, especially in adults with the GA genotype of ESR-beta Rsal. This trial was registered at the Chinese clinical trial registry as ChiCTR-TRC-10001048.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available